Connecting Capital with Innovation

3-5 June 2013
Sheraton Hotel & Towers, Hong Kong
Connecting Capital with Innovation
Co-organisers
"As the world becomes increasingly Asia-centric,
it is essential that our company develops links
and contacts in the Biotech and Investment
communities in Asia. The work of AusBiotech in
proactively assisting
in this through the Asia Biotech Invest summit
enabled us to link in effectively and quickly. We'll
be back."
Sean Parsons, Managing Director, ELLUME
"We were very pleasantly surprised by the
number and calibre of the investors that
attended the meeting. Minomic had a number of
very productive meetings and is pursuing two
strong leads in its capital raising efforts directly
as a result of the Asia Biotech Invest meeting."
Dr Brad Walsh, CEO, MINOMIC INTERNATIONAL
Post-Event Report
Silver Sponsors
www.AsiaBiotechInvest.com
Cocktail Sponsor
3-5 June 2013
Sheraton Hotel & Towers, Hong Kong
Connecting Capital with Innovation
www.AsiaBiotechInvest.com
3-5 June 2013
Sheraton Hotel & Towers, Hong Kong
Connecting Capital with Innovation
Asia Biotech Invest 2013 puts the spotlight on biotech investment
The first edition of the Asia Biotech Invest conference on 4-5 June 2013 was a great success!
Co-organised by AusBiotech and Beacon Events, the event was the first
and biggest biotech showcase ever to be held in Hong Kong and
attracted over 230 high-level delegates from across the life science
community.
Held in the financial hub Hong Kong, the event brought cutting-edge
biotech innovators together with Asia’s investment community to
discover and fund the future of biotech. On both conference days the
conference room and exhibition area was buzzing with excitement and
everyone made full use of the networking and dealmaking opportunities.
Delegates also benefited from lively panel discussions and keynotes by
leading investors, industry advisors, biotech CEOs and big pharma
representatives on such topics as: global and regional biotech
investment, key industry trends, partnering, IP, financing and business
strategies. Plus, 17 biotech companies presented their pipeline and
investment case in 8-minute pitches to the attentive investor audience.
www.AsiaBiotechInvest.com
3-5 June 2013
Sheraton Hotel & Towers, Hong Kong
Connecting Capital with Innovation
Excellent Delegate Mix and Outstanding Overall Feedback
The conference featured a diverse and high-quality mix of delegates and provided excellent networking and learning
opportunities during the two days. Over 47% of the delegates were professional investors, 75% of which were at Clevel or senior management level.
COMPANY TYPE
Research Institute
1%
Pharma
8%
Science Park…
Stock Exchange…
Services
10%
Media
8%
Communications
1%
Academic /
Association
6%
Biotech
13%
Investor
47%
Government
4%
JOB FUNCTIONS - INVESTORS
C-Level /
Senior
Management
75%
Principals /
Associates
20%
Analyst
5%
COUNTRY / REGION - INVESTORS
Malaysia
3%
Korea
1%
United
Singapore
Kingdom USA
2%
4%
4%
Australia
6%
Canada
1%
China
12%
Hong Kong
67%
www.AsiaBiotechInvest.com
“I thought it was an excellent event,
with a quality turnout, a relevant and
accomplished crowd. It was of
optimal size, large enough to have
critical mass and justify the travel to
Hong Kong, small enough to get to
know many of the attendees and
understand their business better than
would otherwise be the case.”
Nicholas C. Ashby, Chief Executive
Officer, CELADON CAPITAL
"It was a very well organised and well
attended event with a pleasingly
large number of investors seriously
interested in Australian biotech
opportunities. It was obvious that
there is significant opportunity for
Australian companies to access
sources of Asian capital through such
a forum. The thought leader panel
discussions within the conference
sparked a lot of questions and helped
flesh out where the Asian industry is
going. The interest we generated for
BioDiem made the event very
worthwhile for us with 2-3 major
leads we are following up."
Julie Phillips, Chief Executive Officer,
BIODIEM
“Thanks for all of your hard work at
the Asia BioTech invest conference in
Hong Kong. I thought that you and
the rest of the Beacon Events team
put on an excellent program and had
some great people at the conference.
Well worth the trip from Australia!”
Jamie Lingham, Chief Executive
Officer, ABSOLUTE IMMIGRATION
3-5 June 2013
Sheraton Hotel & Towers, Hong Kong
Connecting Capital with Innovation
JOB FUNCTIONS - OVERALL
Analyst
2%
BD / Marketing
12%
Senior
Management
36%
C-Level
16%
Investment
Management
18%
Consultant
4%
Research
3%
Regulatory
3%
Others
2%
Media
4%
Malaysia
4% Singapore
3%
Rest of Asia
3%
Hong Kong
55%
Australia
15%
Europe
5%
"Excellent platform for investors and
biotech companies."
Ng Swee Choong, R&D Engineer,
COOK ASIA
"Great connections made with an
excellent program as a bonus."
David Anderson, Deputy Director,
BURNET INSTITUTE
REGION / COUNTRY
North America
5%
“From its first edition, Asia Biotech
Invest is already the "must-go" event
for both biotech investors and fundseekers in Asia.”
Andrew Badrot, Partner and Chief
Executive Officer, CMS ADVISORS
China
10%
“It was such a well-run conference
with so many high quality speakers
and delegates. It was pretty unique to
have heavyweights from Asian
biotech and the investment
community all in one place”
Viren Mahurkar, Chairman
Entrepreneurship and Investment
Committee, ABLE
“I thought the symposium was well
organized and a real success. I
learned a great deal!”
Dr. Michael A. Berry, Managing
Director, DISCOVERY INVESTING
“I was very pleased to have been
involved with the Asia Biotech Invest
event, which I thought was very
worthwhile and extremely well
organised.”
Mark Roberts, Partner, DAVIES
COLLINSON CAVE
www.AsiaBiotechInvest.com
3-5 June 2013
Sheraton Hotel & Towers, Hong Kong
Connecting Capital with Innovation
Distinguished Line-up of Speakers and Panellists
Over 40 industry leaders from big pharmaceutical and biotechnology companies, advisory and consulting firms, stock
exchanges, as well as life science investment companies presented at the conference. We would like to thank them
all including:
Amit Kakar, Head of Healthcare Asia, AVENUE CAPITAL
GROUP
Andrew Badrot, Partner and Chief Executive Officer,
CMS ADVISORS
Anne Kim, Vice President, QUADRIA CAPITAL
Augustine Yee, Asia Pacific Head of Regional and
Corporate Business Development; and China Vice
President of Business Development, ASTRAZENECA
Barry Thomas, Director Asia Pacific, COOK MEDICAL
Dr. Benjamin P. Chen, Managing Partner, IGNATIUS
TRANSACTION PARTNERS
Dr. Bin Li, Managing Director, MORGAN STANLEY
RESEARCH
Dr. Binhui Ni, Head, Strategy, Science Policy & External
Innovation, SANOFI
Dr. Carl Firth, Chief Executive Officer, ASLAN
PHARMACEUTICALS
Catherine Feng, Representative, Beijing Representative
Office, NEW YORK STOCK EXCHANGE
Cherry Lu, Vice President, SEQUOIA CAPITAL
Daniel R. Quon, Managing Director – Asia, SVB CAPITAL
Dr. Darren Ji, Global Head of Roche Partnering, Asia and
Emerging Markets, ROCHE
Dr. David Anderson, Associate Professor, BURNET
INSTITUTE
Dr. David Baghurst, Managing Director, ISIS
ENTERPRISE ASIA
Davis Yang, Principal, BVCF
Dr. Esra Ogru, Chief Executive Officer, PHOSPHAGENICS
Dr. Fintan Walton, Founder and Chief Executive Officer,
PHARMAVENTURES
Frank Giglio, General Manager Asia-Pacific, NASDAQ
OMX
Dr. Gaspar Taroncher-Oldenburg, Managing Editor and
Associate Publisher Science Business Exchange (SciBX),
NATURE PUBLISHING GROUP
James Williams, Co-founder and Investment Director,
YUUWA CAPITAL
Jamie Lingham, Chief Executive Officer, ABSOLUTE
IMMIGRATION SERVICES
Jeremy Curnock Cook, Managing Director, BIOSCIENCE
MANAGERS
Dr. Jimmy Zhang, Managing Director MSD Early
Investments – Greater China, MERCK & CO; Chairman,
BAYHELIX
Dr. Jing-Shan “Jennifer” Hu, Vice President, Head of
Innovation Center China, Global Drug Discovery, BAYER
HEALTHCARE
Dr. Jonathan Wang, Senior Managing Director,
ORBIMED ASIA
Dr. Julian Chick, Chief Operating Officer, ALLIED
HEALTHCARE GROUP
Kimberly Nearing, Managing Director, CEDRUS
INVESTMENTS
Lawrence Wang, Managing Director, PRIMAVERA
CAPITAL
Magen Xia, Principal, BOSTON CONSULTING GROUP
www.AsiaBiotechInvest.com
3-5 June 2013
Sheraton Hotel & Towers, Hong Kong
Connecting Capital with Innovation
Mark Roberts, Partner, DAVIES COLLISON CAVE
Dr. Michael A. Berry, Managing Director, DISCOVERY
INVESTING
Dr. Min Cui, Managing Director, DECHENG CAPITAL
Ming-Chung Wong, Founder and Chief Executive
Officer, LOTUS INNOVATIVE HEALTH
Nicholas C. Ashby, Chief Executive Officer, CELADON
CAPITAL
Nisa Leung, Partner, QIMING VENTURE PARTNERS
Paul A. Hopper, Head of Life Science and Biotechnology,
CAPELLO CAPITAL
Rhenu Bhuller, Vice President Healthcare Asia Pacific,
FROST & SULLIVAN
Rob Scott, Director, CHINA BLUESKY VENTURES
Sabrina Chan, Executive Director, HONG KONG
ASSOCIATION OF THE PHARMACEUTICAL INDUSTRY
(HKAPI)
Sam Olsen, Managing Director and Head of Asia
Security Practice, KROLL ADVISORY SOLUTIONS
Scott Power, Director of Research, RBS MORGANS
Victor E. Tong Jr., Principal, DECHENG CAPITAL
Viren Mahurkar, Chairman Entrepreneurship and
Investment Committee, ABLE
Dr. Yi Shi, Managing Director, LILLY ASIA VENTURES
Dr. Yuan-Hua Ding, Senior Director, Head of External
R&D Innovation, Asia/Pacific, Worldwide R&D, PFIZER
Biotech in a Day Workshop
On Monday 3 June, prior to the Asia Biotech Invest conference, the Biotech in a Day course was hosted for those
delegates keen to learn more about the fundamentals of biotechnology. The hands-on workshop explained the
building blocks of biotechnology in easy to understand terms and introduced the 18 delegates to the key biomedical
developments that are revolutionising the way medicines and therapeutic strategies are being developed today. The
intensive course was conducted by:
Dr. Vanya Loroch, CEO and Senior Trainer, LOROCH COMMUNICATION & TRAINING IN LIFE SCIENCES
Prof. Dr. Reinhard Renneberg, Department of Chemistry, HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
www.AsiaBiotechInvest.com
3-5 June 2013
Sheraton Hotel & Towers, Hong Kong
Connecting Capital with Innovation
The conference was attended by delegates from the following companies:
8T8 Capital Ltd
Boston Consulting Group
EcoQuest
ABLE
Bourse Communications
Ellis Brady Management HK
Absolute Immigration Services
Buchan Consulting
Ellume
AK Partners HK
Burnet Institute
Etoile Asset Management
Allied Healthcare Group
Business Succession Partners
Evolva Biotech
Altruist Financial Group
BVCF
Ants Media Group
Caitong International Asset
Management
Fortune Time Capital Holding
Group
Franklin Templeton Investments
Asia
AP Capital Group
Capvest & Associates
Frost & Sullivan Singapore
Asia Pacific Investment Advisors
ASLAN Pharmaceuticals
AstraZeneca China
Cassiopeia Management Strategy
Advisors - CMS Pharma
CCB International Asset
Management
CCTV News English Hong Kong
Bureau
Global Bioenergies
Global Mining Capital Corporation
Gottex Penjing Asset Management
Australian Trade Commission
Cedrus Investments HK
Green Mountains Investments
Avenue Capital Group
Celadon Capital Malaysia
Greenwoods Asset Management
AyoxxA Living Health Technologies
Chepstow Capital Advisors
Guangdong International Capital
Ballingal Investment Advisors
China BlueSky Ventures
GYK Holdings
Baring Private Equity Partners Asia
Clinuvel
Harmony Asset Management
Baron Group - Baron Capital
CMS Asset Management HK
Hong Kong Baptist University
Bayer Healthcare
Cook Asia
BioDiem
Cook Medical
BioLife Science
Creata Group
Bioscience Managers
DAC Financial Management China
Biosell
Davies Collison Cave
Biotech Recruitment Consultants
Decheng Capital
Ignatius Transaction Partners
Biotivia
Dechert
IMS Health
Biotron
Deltec Capital
Infinity Group
Bloomberg
Development Center for
Biotechnology
Innovation & Technology
Commission - Govt HKSAR
BOCI-Prudential Asset
Management
Dezan Shira & Associates
Intellectual Property Watch
www.AsiaBiotechInvest.com
Hong Kong Biotechnology
Organization
Hong Kong Institute of
Biotechnology
Hong Kong Investment Funds
Association
Hong Kong Science & Technology
Parks
IAIR -International Alternative
Investment Review
3-5 June 2013
Sheraton Hotel & Towers, Hong Kong
Connecting Capital with Innovation
Boehringer Ingelheim
Pharmaceuticals
Discovery Investing
Invest Hong Kong
Invion
NexVet BioPharma
Sinovest Capital
IRasia.com
NYSE Euronext
South China Morning Post
Isis Innovation Asia
Optivest Capital
State Government of Victoria
Australia
JAG Investments
OrbiMed Asia
STIC Investment
JPMorgan Asset Management
Real Assets Asia
Pacific West Asia Asset
Management
Pfizer Global Research &
Development
Kaiwu Capital
PharmaVentures
SVB Global
Kareus Therapeutics
Phosphagenics
Taipei Economic & Cultural Office
Khazanah Nasional Berhad
Polynoma
Telezon
Kroll Associates Asia
Primavera Capital
The Bank of East Asia
Leon CVM Capital Management
Hong Kong
Qiming Ventures
LGT Capital Partners Asia Pacific
QRxPharma
Lilly Asia Ventures
Quadria Capital
Lim Global Investment &
Research
Qualita
Liomer Holdings
Quam
The Longreach Group
Loroch CTLS
Queensland Government Trade &
Investment Office
The NASDAQ OMX
Lotus Innovative Health
Racepoint Group
The University of Hong Kong
M H Carnegie & Co
RBS Morgans
Tian An China Investments
Malaysian Biotechnology
Corporation
RHTLaw Taylor Wessing
Tripod Capital
Mandie Consulting
RimAsia Capital Partners
UK Trade & Investment - British
Consulate-General Hong Kong
Merck & Co
Roche Partnering Asia
Valiant Ocean Investment
Mergermarket
Rock Spring Ventures
Ventac Partners HK
Minomic International
RRJ Management HK
Vivo Ventures
Morgan Stanley Asia
Saba Capital
Wellcome Trust
Muse Capital
Sanofi
West Pharmaceutical Packaging
India
MZ Australia
SciBX
William A Cook Australia
Nan Fung Group
Sequoia Capital
Yuuwa Capital
Nature Publishing Group
Shaw Kwei & Partners
Jiwa Bio-Pharm Holdings
www.AsiaBiotechInvest.com
Stratagem Capital
Sumitomo Mitsui Asset
Management HK
The Chinese University of Hong
Kong
The Hong Kong Association of the
Pharmaceutical Industry
The Hong Kong Polytechnic
University
The Hong Kong University of
Science & Technology
3-5 June 2013
Sheraton Hotel & Towers, Hong Kong
Connecting Capital with Innovation
The Following Sponsors, Biotech Companies, Associations,
and Media Supported Asia Biotech Invest 2013
Silver Sponsors
Cocktail Sponsor
Presenting Companies
Local Host Partners
Supporting Associations
Supporting Organisations
PR Partners
Media Partners
www.AsiaBiotechInvest.com
3-5 June 2013
Sheraton Hotel & Towers, Hong Kong
Connecting Capital with Innovation
“It was such a well-run conference with so many
high quality speakers and delegates. It was pretty
unique to have heavyweights from Asian biotech
and the investment community all in one place”
Viren Mahurkar
Chairman Entrepreneurship and Investment
Committee
ABLE
“Asia Biotech Invest offers a unique venue for
all life science stakeholders– entrepreneurs,
large pharma and biotech, and investors–to
discuss the latest trends and opportunities for
life science investing in Asia and cultivates indepth discussion across a wide range of topics
from regulatory to partnerships to raising
capital.”
Victor E. Tong Jr.
Principal
DECHENG CAPITAL
"Dynamic platform of Biotech advocates
sharing intelligence, challenges, and
inspirations."
Cecilia Chan
Assistant Trade Commissioner
UK TRADE & INVESTMENT
“It was indeed an excellent conference and very
interesting topics discussed and great people to
meet!”
Magen Xia
Principal Consultant
BOSTON CONSULTING GROUP
www.AsiaBiotechInvest.com
3-5 June 2014
Sheraton Hotel & Towers, Hong Kong
Connecting Capital with Innovation
See You at Asia Biotech Invest 2014
Asia Biotech Invest will return to Hong Kong from 3-5 June 2014! Come join us again next year for even more biotech
company presentations, insightful discussions with industry leaders, to meet more people and close more deals!
What can you expect at Asia Biotech Invest 2014:
•
Wider range of biotech company spotlight presentations
•
Extended exhibition and networking sessions
•
Exclusive access to BioInvest Partnering, our advanced online partnering system to set up 1-on-1 meetings
•
Well-researched, high-quality programme that will update you on all relevant trends in biotech investment in Asia
and globally
•
International speaker line-up of experts who are at the forefront of biotech investing and partnering
•
Dedicated country sessions to zoom in on Asia’s emerging biotech hubs
•
Return of the invaluable Biotech in a Day workshop
•
More professional investors looking for promising biotech investment opportunities
To find out how you can participate in Asia Biotech Invest 2014, contact our events team today.
Sponsorship and Exhibition Enquiries
Australia & New Zealand
Hayley Laing
+613 9828 1400
[email protected]
Rest of the World
King Tai
+852 2531 6125
[email protected]
Speaking Enquiries
Australia & New Zealand
Hayley Laing
+613 9828 1400
[email protected]
Rest of the World
Lot de Jongh
+852 2531 6140
[email protected]
Marketing enquiries
Winnie Louie
+852 2531 6121
[email protected]
www.AsiaBiotechInvest.com

Download Report